Membrane interaction of α-synuclein in different aggregation states

Journal of Parkinson's Disease

Volumn 1, Issue 4, 2011, Pages 359-371

  Grey, Marie ^a,b   Linse, Sara ^a   Nilsson, Hanna ^a   Brundin, Patrik ^b   Sparr, Emma ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

synuclein; aggregation; amyloid; fibril; lipid bilayers; membrane; oligomer; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; CARDIOLIPIN; DIOLEOYLPHOSPHATIDYLCHOLINE; MONOMER; RHODAMINE B; THREO 3,4 DIHYDROXYPHENYLSERINE;

ANION EXCHANGE; ARTICLE; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; FIBER; FLUORESCENCE MICROSCOPY; LAMELLAR BODY; LIPID COMPOSITION; MEMBRANE TRANSPORT; MITOCHONDRIAL MEMBRANE POTENTIAL; PHOSPHOLIPID BILAYER; PHOSPHOLIPID MEMBRANE; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SURFACE PROPERTY;

ALPHA-SYNUCLEIN; HUMANS; KINETICS; LIPID BILAYERS; MEMBRANE LIPIDS; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, SECONDARY; UNILAMELLAR LIPOSOMES;

EID: 84858268438     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11067     Document Type: Article

References (65)

1. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, & Double KL (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664.
2. Halliday GM, Holton JL, Revesz T, & Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (Berl), 122, 187-204.
3. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, PikeB, Root H, Rubenstein. J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
4. Kruger R,KuhnW, Muller T,Woitalla D, Graeber M,Kosel S, Przuntek H, Epplen JT, Schols L, & Riess O (1998) Ala30pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18, 106-108.
5. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, & de Yebenes JG (2004) The new mutation, e46k, of alphasynuclein causes Parkinson and lewy body dementia. Ann Neurol, 55, 164-173.
6. Chartier-Harlin MC, Kachergus. J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, & DesteeA(2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
7. Singleton AB, Farrer M, Johnson. J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
8. Bartels T, Choi JG, & Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477, 107-110.
9. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T,Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, & Riek R (2011) In vivo demonstration that alphasynuclein oligomers are toxic. Proc Natl Acad Sci U S A, 108, 4194-4199.
10. Wakabayashi K, Tanji K, Mori F, & Takahashi H (2007) The lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology, 27, 494-506.
11. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B,&KostkaM(2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci, 27, 9220-9232.
12. Giehm L, Svergun DI, Otzen DE, & Vestergaard B (2011) Low-resolution structure of a vesicle disrupting-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci U S A, 108, 3246-3251.
13. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, & Lansbury Jr PT (2002) [alpha]-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol, 322, 1089-1102.
14. Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, & Edwards RH (2008) Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci, 28, 12305-12317.
15. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, & Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex i in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem, 283, 9089-9100.
16. Middleton ER, & Rhoades E (2010) Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys, J 99, 2279-2288.
17. Stockl M, Fischer P, Wanker E, & Herrmann A (2008) Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. J Mol Biol, 375, 1394-1404.
18. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B,Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, & Edwards RH (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem, 286, 20710-20726.
19. Quinn PJ, Kagan VE (2002) eds, Subcellular Biochemistry: Phospholipid metabolism in apoptosis, vol. 36, Kluwer Academic/ Plenum Publishers, London.
20. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, & Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med, 14, 501-503.
21. Kordower JH, Chu Y, Hauser RA, Freeman TB, & Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med, 14, 504-506.
22. Brundin P, Li JY, Holton JL, Lindvall O, & Revesz T (2008) Research in motion: The enigma of Parkinson's disease pathology spread. Nat Rev Neurosci, 9, 741-745.
23. Angot E, Steiner JA, Hansen C, Li JY, & Brundin P (2010) Are synucleinopathies prion-like disorders? Lancet Neurol, 9, 1128-1138.
24. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, & Masliah E (2010) Cell-to-cell transmission of non-prion protein aggregates. Nature reviews. Neurology, 6, 702-706.
25. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, & Brundin P (2011) Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest, 121, 715-725.
26. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, & Collier TJ (2011) Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis, 43, 552-557.
27. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E,&Lee SJ (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A, 106, 13010-13015.
28. Angelova MI, & Dimitrov DS (1986) Liposome electroformation. Faraday Discuss, 81, 303-311.
29. Dimitrov DS,&Angelova MI (1988) Lipid swelling and liposome formation mediated by electric-fields. Bioelectrochem Bioenerg, 19, 323-336.
30. Ambroggio EE, & Bagatolli LA (2009) Membrane-active peptides: Methods and results on structure and function. In: Castanho M, editor. Giant unilamellar vesicles, fluorescence microscopy and lipid-peptide interactions. La Jolla, International University Line, CA, pp. 179-200.
31. Linse S, Hellstrand E, Boland B, & Walsh DM (2010) Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. Acs Chemical Neuroscience 1, 13-18.
32. Biancalana M, Makabe K,Koide A,&Koide S (2009) Molecular mechanism of thioflavin-t binding to the surface of beta-rich peptide self-assemblies. J Mol Biol, 385, 1052-1063.
33. Hellstrand E, Sparr E, & Linse S (2010) Retardation of abeta fibril formation by phospholipid vesicles depends on membrane phase behavior. Biophys J, 98, 2206-2214.
34. Hoyer W, Cherny D, Subramaniam V, & Jovin TM (2004) Impact of the acidic c-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry (Mosc), 43, 16233-16242.
35. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jackle H, Eimer S, Schulz JB, Griesinger C, & Zweckstetter M (2009) Prefibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J, 28, 3256-3268.
36. Giannakis E, Pacifico. J, Smith DP, Hung LW, Masters CL, Cappai R,Wade JD,&Barnham KJ (2008) Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta, 1778, 1112-1119.
37. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, KokerM, Carvalho F, Hyman BT, &McLean PJ (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoSONE, 3, e1867.
38. Cho M-K, Nodet G, Kim H-Y, Jensen MR, Bernado P, Fernandez CO, Becker S, Blackledge M, & Zweckstetter M (2009) Structural characterization of alpha-synuclein in an aggregation prone state. Protein Sci, 18, 1840-1846.
39. Wu K-P, Weinstock DS, Narayanan C, Levy RM, & Baum J (2009) Structural reorganization of [alpha]-synuclein at low ph observed by nmr and remd simulations. J Mol Biol, 391, 784-796.
40. Uversky VN, Li J, & Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem, 276, 10737-10744.
41. Giehm L,&Otzen DE (2010) Strategies to increase the reproducibility of protein fibrillization in plate reader assays. Anal Biochem, 400, 270-281.
42. Kim H-Y, Cho M-K, Kumar A, Maier E, Siebenhaar C, Becker S, Fernandez CO, Lashuel HA, Benz R, Lange A, & Zweckstetter M (2009) Structural properties of pore-forming oligomers of-synuclein. J Am Chem Soc, 131, 17482-17489.
43. Lee H-J, Patel S, & Lee S-J (2005) Intravesicular localization and exocytosis of {alpha}-synuclein and its aggregates. J Neurosci, 25, 6016-6024.
44. Cole NB, DiEuliis D, Leo P, Mitchell DC, & Nussbaum RL (2008) Mitochondrial translocation of [alpha]-synuclein is promoted by intracellular acidification. Exp Cell Res, 314, 2076-2089.
45. Takahashi M, Ko LW, Kulathingal J, Jiang P, Sevlever D, & Yen SH (2007) Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated ck2 and cathepsin d. Eur J Neurosci, 26, 863-874.
46. Li W, Jiang H, Song N, & Xie J (2011) Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in sk-n-sh cells. Neurotox Res, 19, 435-442.
47. Ramakrishnan M, Jensen PH, & Marsh D (2003) Alphasynuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry (Mosc), 42, 12919-12926.
48. Lee HJ, Choi C, & Lee SJ (2002) Membrane-bound alphasynuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem, 277, 671-678.
49. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC,&Lansbury PT Jr (2001)Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (Mosc), 40, 7812-7819.
50. Smith DP, Tew DJ, Hill AF, Bottomley SP, Masters CL, Barnham KJ, & Cappai R (2008) Formation of a high affinity lipid-binding intermediate during the early aggregation phase of a-synuclein. Biochemistry (Mosc), 47, 1425-1434.
51. Hellstrand E, Boland B, Walsh DM, & Linse S (2010) Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. Acs Chemical Neuroscience, 1, 13-18.
52. van Rooijen BD, Claessens MM, & Subramaniam V (2010) Membrane permeabilization by oligomeric alpha-synuclein: In search of the mechanism. PLoS ONE, 5, e14292.
53. Rhoades E, Ramlall TF, Webb WW, & Eliezer D (2006) Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J, 90, 4692-4700.
54. van Rooijen BD, Claessens MM, & Subramaniam V (2008) Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing. FEBS Lett, 582, 3788-3792.
55. Lewis R, &McElhaney R (2009) The physicochemical properties of cardiolipin bilayers and cardiolipin-containing lipid membranes. Biochimica et Biophysica Acta (BBA) -Biomembranes, 1788, 2069-2079.
56. Pope S, Land JM, & Heales SJR (2008) Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochimica Et Biophysica Acta-Bioenergetics, 1777, 794-799.
57. Devi L, & Anandatheerthavarada HK (2010) Mitochondrial trafficking of app and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta, 1802, 11-19.
58. Sparr E, Engel MF, Sakharov DV, Sprong M, Jacobs J, de Kruijff B, Hoppener JW, & Killian JA (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett, 577, 117-120.
59. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, SchroeckhV, Leisner C, Lutkepohl T, Shtrasburg S, Rocken C, Pras M, LinkeRP, Diekmann S,&Fandrich M(2005) Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci U S A, 102, 6297-6302.
60. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, & Lee VM (2011) Exogenous alpha-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71.
61. Stockl M, Claessens MM, & Subramaniam V (2012) Kinetic measurements give new insights into lipid membrane permeabilization by alpha-synuclein oligomers. Mol Biosyst, 8, 338-345.
62. Yang AJ, Chandswangbhuvana D, Margol L, & Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid abeta1-42 pathogenesis. J Neurosci Res, 52, 691-698.
63. Lee H-J, Suk J-E, Bae E-J, Lee J-H, Paik SR, & Lee SJ (2008) Assembly-dependent endocytosis and clearance of extracellular [alpha]-synuclein. Int J Biochem Cell Biol, 40, 1835-1849.
64. PandeyAP, Haque F, Rochet JC,&Hovis JS (2009) Clustering of alpha-synuclein on supported lipid bilayers: Role of anionic lipid, protein, and divalent ion concentration. Biophys J, 96, 540-551.
65. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, & Lee SJ (2010) Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem, 113, 1263-1274.